• Species Reactivity

  Human

• Specificity

  Detects human ENPP-1 in direct ELISAs and Western blots. In direct ELISAs, less than 3% cross-reactivity with recombinant human ENPP-2 and recombinant mouse ENPP-2 is observed after removal of cross-reactivity with human ENPP-2.

• Source

  Polyclonal Sheep IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human ENPP-2-1-2    
  Asp49-Trp144 (ENPP-2), Val191-Leu591 (ENPP-1), Asn532-Ile863 (ENPP-2). Cross-reactivity with human ENPP-2 was removed from the final product.    
  Accession # Q13822 (ENPP-2) P22413 (ENPP-1)

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 µg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Sterile PBS to a final concentration of 0.2 mg/mL.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: ENPP-1

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP-1) is a transmembrane glycoprotein that hydrolyzes nucleotides and nucleotide derivatives with the formation of nucleotide-5’-monophosphates. It is inserted into the plasma membrane by an N‑terminal transmembrane domain. Human ENPP-1 has a small N-terminal cytoplasmic domain and a large C-terminal region containing two somatomedin B-like domains, a catalytic domain and a nuclease-like domain in the extracellular space (1). Defects in the ENPP-1 gene cause arterial calcification and bone mineralization abnormalities (2). ENPP-1 polymorphism or overexpression is also associated with obesity, type II diabetes and insulin resistance, which makes modulation of ENPP-1 activity one of the targets to treat insulin resistance and related diseases (1).

• References:

   

1. Goldfine, I.D. et al. (2010) Endocrine Reviews. 29:62.

2. Hessle, L. et al. (2002) Proc. Natl. Acad. Sci. 99:9445.

• Long Name:

  Ectonucleotide Pyrophosphatase/Phosphodiesterase 1

• Entrez Gene IDs:

  5167 (Human)

• Alternate Names:

  ectonucleotide pyrophosphatase/phosphodiesterase 1; E-NPP 1; ENPP1; ENPP-1; Ly-41 Antigen; M6S1; M6S1NPP1; Membrane component chromosome 6 surface marker 1; membrane component, chromosome 6, surface marker 1; NPP1; NPPS; NPPSalkaline phosphodiesterase 1; PC1; PC-1; PCA1; PCA1ARHR2; PDNP1; PDNP1ectonucleotide pyrophosphatase/phosphodiesterase family member 1; Phosphodiesterase I/nucleotide pyrophosphatase 1; plasma-cell membrane glycoprotein 1; Plasma-cell membrane glycoprotein PC-1